Treatment Information

Back

Melanoma treatment details. Immunotherapy.

Peking University Cancer Hospital & Institute, Beijing, China.

Survival: monthsCountry:China
Toxiciy Grade:4City/State/Province:Beijing
Treatments:ImmunotherapyHospital:Peking University Cancer Hospital & Institute
Drugs:Journal:Link
Date:Aug 2013

Description:

Patients:
This phase 2 study involved mucosal melanoma patients who were divided into two separate treatment groups. Group A consisted of 63 patients with a median age of 55 years; 39.7% were male. Group B had 63 patients with a median age of 59 years; 36.5% were male.

Treatment:
Patients in group A were treated with high dose interferon alpha 2b (IFN-a2b), an immune therapy agent.

Patients in group B were treated with the chemotherapy agents temozolomide and cisplatin.

Toxicities:
The most severe toxicities in group A were of grade 4 and included grade 3-4 liver toxicity and leucopenia.

The most severe toxicities in group B were of grade 4 and included grade 3-4 anemia, anorexia, and nausea/vomiting.

Results:
The median overall survival rate for groups A and B were 40.4 and 48.7 months, respectively.

Correspondence: Dr. Jun Guo; email: guoj307@126.com



Back